Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017

Product Code GDA00738
Publication Date June 2010
Publisher GlobalData
Product Type Report
Pages 54
ISBN Number not applicable
Change currency
PDF £1,265.00 €1,523 $2,000 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017

Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released a new report, "Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector. GlobalData estimates the global type 1 diabetes therapeutics market to have been valued at $2.7 billion in 2009. It is forecast to grow at 6.1% annually for the next seven years to reach $4.4 billion by 2017. This growth is primarily attributed to the increase in the average cost of therapy for type 1 diabetes and increases in the diseased and treatment seeking populations. The available treatment options are moderately successful in meeting the market demand leading to a moderate level of unmet need. A significant market potential exists to be exploited by any new entrant that will cater to the unmet needs for more convenient products with better efficacy and safety. GlobalData finds that the emerging therapies in the pipeline are expected to capture a small portion of the unmet need. The pipeline for type 1 diabetes appears to be moderately strong. Despite the high proportion of first-in-class drugs in the pipeline, the pipeline is not very strong as the development stage products are not likely to cater to the needs of all type 1 diabetes patients. While the pipeline products are not strong enough to impact the current market considerably, the success of these products will drive the market in the long run.

Scope

The scope of the report includes:

  • Annualized global type 1 diabetes market revenues data from data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
  • Analysis of the current and future market competition in the global type 1 diabetes market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type 1 diabetes.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 1 diabetes market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global type 1 diabetes market landscape? - Identify, understand and capitalize.

Contents

  • 1 Table of contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Type 1 Diabetes Therapeutics Market: Market Characterization
    • 2.1 Overview
    • 2.2 Type 1 Diabetes Market Size
    • 2.3 Type 1 Diabetes Therapeutics Market Forecast and CAGR
    • 2.4 Drivers and Barriers for the Type 1 Diabetes Therapeutics Market
      • 2.4.1 Drivers for the Type 1 Diabetes Therapeutics Market
      • 2.4.2 Restraints for the Type 1 Diabetes Therapeutics Market
    • 2.5 Opportunity and Unmet Need
    • 2.6 Key Takeaway
  • 3 Type 1 Diabetes Therapeutics Market: Competitive Assessment
    • 3.1 Overview
    • 3.2 Strategic Competitor Assessment
    • 3.3 Product Profile for the Major Marketed Products in the Type 1 Diabetes Disease Market
      • 3.3.1 Lantus (Insulin Glargine)
      • 3.3.2 Humulin (Human Insulin)
      • 3.3.3 Humalog (Insulin Lispro)
      • 3.3.4 Novolog (Insulin Aspart)
      • 3.3.5 Novolin (Human Insulin)
      • 3.3.6 Apidra (Insulin Glulisine)
      • 3.3.7 Levemir (Insulin Detemir)
    • 3.4 Key Takeaway
  • 4 Type 1 Diabetes Therapeutics Market: Pipeline Assessment
    • 4.1 Overview
    • 4.2 Strategic Pipeline Assessment
      • 4.2.1 Technology Trends Analytic Framework
    • 4.3 Type 1 Diabetes Therapeutics - Promising Drugs under Clinical Development
    • 4.4 Molecule Profile for Promising Drugs under Clinical Development
      • 4.4.1 rhGAD65 (Diamyd)
      • 4.4.2 DiaPep277
      • 4.4.3 Otelixizumab
      • 4.4.4 Oral-lyn
    • 4.5 Type 1 Diabetes Therapeutics Market - Clinical Pipeline by Mechanism of Action
    • 4.6 Type 1 Diabetes Pipeline - Pipeline by Clinical Phases of Development
      • 4.6.1 Type 1 Diabetes Therapeutics - Filed and Approved Drugs
      • 4.6.2 Type 1 Diabetes Therapeutics - Phase III Clinical Pipeline
      • 4.6.3 Type 1 Diabetes Therapeutics - Phase II Clinical Pipeline
      • 4.6.4 Type 1 Diabetes Therapeutics - Phase I Clinical Pipeline
      • 4.6.5 Type 1 Diabetes Therapeutics - Preclinical-Discovery Pipeline
    • 4.7 Key Takeaway
  • 5 Type 1 Diabetes Market: Implications for Future Market Competition
  • 6 Type Diabetes Therapeutics Market: Future Players in the Type 1 Diabetes Therapeutics Market
    • 6.1 Introduction
    • 6.2 Novo Nordisk
      • 6.2.1 Business Description
      • 6.2.2 Metabolic Disorders Portfolio
      • 6.2.3 Type 1 Diabetes Pipeline Portfolio
    • 6.3 GlaxoSmithKline
      • 6.3.1 Business Description
      • 6.3.2 Metabolic Disorders Portfolio
      • 6.3.3 Type 1 Diabetes Pipeline Portfolio
    • 6.4 Eli Lilly
      • 6.4.1 Business Description
      • 6.4.2 Metabolic Disorders Portfolio
      • 6.4.3 Type 1 Diabetes Pipeline Portfolio
    • 6.5 Sanofi-Aventis
      • 6.5.1 Business Description
      • 6.5.2 Metabolic Disorders Portfolio
      • 6.5.3 Type 1 Diabetes Pipeline Portfolio
  • 7 Type 1 Diabetes Therapeutics Market: Appendix
    • 7.1 Definitions
    • 7.2 Scope of Pipeline Research
    • 7.3 Abbreviations
    • 7.4 Research Methodology
      • 7.4.1 Coverage
      • 7.4.2 Secondary Research
      • 7.4.3 Forecasting
      • 7.4.4 Primary Research
      • 7.4.5 Expert Panel Validation
    • 7.5 Contact Us
    • 7.6 Disclaimer
    • 7.7 Sources
  • 1.1 List of Tables
    • Table 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009
    • Table 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017
    • Table 3: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Efficacy, 2010
    • Table 4: Type 1 Diabetes Therapeutics Market, Lantus, Adverse Events in 28-Week Clinical Trials of Adults and Children With Type 1 Diabetes, 2010
    • Table 5: Type 1 Diabetes Therapeutics Market, Lantus, Clinical Studies Outcome for Safety, 2010
    • Table 6: Humulin - Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies for Type 1 Diabetes, 2010
    • Table 7: Humulin - Results of Three Month Cross-Over Studies Comparing Humulin with Humalog in Type 1 Diabetes, 2010
    • Table 8: Type 1 Diabetes Therapeutics Market, Humalog, Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies, 2010
    • Table 9: Humalog - Results of a Two Month Study Comparing the Use of Humalog and Humulin With Sulfonyluria (SU) Therapy, 2010
    • Table 10: Type 1 Diabetes Therapeutics Market, Novolog, Glycemic Parameters at the End of 24 Week Study, 2010
    • Table 11: Apidra - Efficacy Result of 26-Week Study Comparing Apidra with Insulin Lispro, 2010
    • Table 12: Apidra - Efficacy Result of 26-Week Study Comparing Apidra with Regular Insulin
    • Table 13: Apidra - Adverse Reactions Observed in Pooled Studies in Type 1 Diabetic Adults, 2010
    • Table 14: Levemir - Efficacy Result in 16-Week Non Blinded Study, 2010
    • Table 15: Major Marketed Products Comparison in the Type 1 Diabetes Therapeutics Market, 2010
    • Table 16: Type 1 Diabetes Therapeutics - Most Promising Drugs Under Clinical Development, 2010
    • Table 17: Type 1 Diabetes Therapeutics - Filed and Approved Drugs, 2010
    • Table 18: Type 1 Diabetes Therapeutics - Phase III Clinical Pipeline, 2010
    • Table 19: Type 1 Diabetes Therapeutics - Phase II Clinical Pipeline, 2010
    • Table 20: Type 1 Diabetes Therapeutics - Phase I Clinical Pipeline, 2010
    • Table 21: Type 1 Diabetes Therapeutics - Preclinical-Discovery Pipeline, 2010
    • Table 22: Genzyme - Metabolic Disorders Marketed Products, 2010
    • Table 23: Novo Nordisk - Metabolic Disorders Pipeline Products, 2010
    • Table 24: GlaxoSmithKline - Metabolic Disorders Marketed Products, 2010
    • Table 25: GlaxoSmithKline - Metabolic Disorders Pipeline Products, 2010
    • Table 26: Eli Lilly - Metabolic Disorders Marketed Products, 2010
    • Table 27: Eli Lilly - Metabolic Disorders Pipeline Products, 2010
    • Table 28: Sanofi-Aventis - Metabolic Disorders Marketed Products, 2010
    • Table 29: Sanofi-Aventis - Metabolic Disorders Pipeline Products, 2010
  • 1.2 List of Figures
    • Figure 1: Type 1 Diabetes Therapeutics Market, Global, Revenues ($bn), 2001-2009
    • Figure 2: Type 1 Diabetes Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2017
    • Figure 3: Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics Market, 2010
    • Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Type 1 Diabetes Therapeutics, 2010
    • Figure 5: Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics Pipeline, 2010
    • Figure 6: Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics Pipeline - Description, 2010
    • Figure 7: Type 1 Diabetes Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010
    • Figure 8: Type 1 Diabetes Therapeutics Pipeline by Phase of Clinical Development, 2010
    • Figure 9: Implications for Future Market Competition in the Type 1 Diabetes Market, 2010
    • Figure 10: Type 1 Diabetes Therapeutics Market - Clinical Pipeline by Company, 2010
    • Figure 11: GlobalData Methodology, 2010
    • Figure 12: GlobalData Market Forecasting Model, 2010